Characterization of a pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases 2 and 5 and aurora A with pro-apoptotic and anti-angiogenic activity in vitro

Chemical Biology and Drug Design

Volumn 86, Issue 6, 2015, Pages 1528-1540

  Řezníčková, Eva ^a   Weitensteiner, Sabine ^b   Havlíček, Libor ^c   Jorda, Radek ^a   Gucký, Tomáš ^a   Berka, Karel ^a   Bazgier, Václav ^a   Zahler, Stefan ^b   Kryštof, Vladimír ^a   Strnad, Miroslav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

angiogenesis; apoptosis; aurora A; cyclin dependent kinase; inhibitor; pyrazolo 4,3 d pyrimidine

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR; DINACICLIB; HISTONE H3; JNJ 7706621; NOCODAZOLE; PYRIMIDINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG; AURKA PROTEIN, HUMAN; AURORA A KINASE; CDK2 PROTEIN, HUMAN; CDK5 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DNA CONTENT; DNA REPLICATION; DOWN REGULATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; FLOW CYTOMETRY; HCT116 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IMMUNOBLOTTING; MESSENGER RNA SYNTHESIS; MOLECULAR MODEL; NUCLEOPHILICITY; PRIORITY JOURNAL; PRO APOPTOTIC ACTIVITY; PROTEIN DEPHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; HCT 116 CELL LINE; MOLECULAR DOCKING; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE A; CELL CYCLE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84956575802     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12618     Document Type: Article

References (50)

1. Hanahan D., Weinberg R.A., (2011) Hallmarks of cancer: the next generation. Cell; 144: 646-674.
2. Malumbres M., Barbacid M., (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer; 9: 153-166.
3. Payton M., Chung G., Yakowec P., Wong A., Powers D., Xiong L., Zhang N., Leal J., Bush T.L., Santora V., Askew B., Tasker A., Radinsky R., Kendall R., Coats S., (2006) Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res; 66: 4299-4308.
4. Tetsu O., McCormick F., (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell; 3: 233-245.
5. Krystof V., Uldrijan S., (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets; 11: 291-302.
6. Lapenna S., Giordano A., (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov; 8: 547-566.
7. Santamaria D., Barriere C., Cerqueira A., Hunt S., Tardy C., Newton K., Caceres J.F., Dubus P., Malumbres M., Barbacid M., (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature; 448: 811-815.
8. Galons H., Oumata N., Meijer L., (2010) Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat; 20: 377-404.
9. Chen R., Keating M.J., Gandhi V., Plunkett W., (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood; 106: 2513-2519.
10. MacCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., Lane D.P., Green S.R., (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res; 65: 5399-5407.
11. Manohar S.M., Rathos M.J., Sonawane V., Rao S.V., Joshi K.S., (2011) Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res; 35: 821-830.
12. Canduri F., Peres P.C., Caceres R.A., de Azevedo W.F., (2008) CDK9 as a potential target for drug development. Med Chem; 4: 210-218.
13. Ali M.A., Choy H., Habib A.A., Saha D., (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia; 9: 370-381.
14. Melillo G., Sausville E.A., Cloud K., Lahusen T., Varesio L., Senderowicz A.M., (1999) Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res; 59: 5433-5437.
15. Scholz A., Wagner K., Welzel M., Remlinger F., Wiedenmann B., Siemeister G., Rosewicz S., Detjen K.M., (2009) The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut; 58: 261-270.
16. Liebl J., Weitensteiner S.B., Vereb G., Takacs L., Furst R., Vollmar A.M., Zahler S., (2010) Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem; 285: 35932-35943.
17. Zahler S., Liebl J., Furst R., Vollmar A.M., (2010) Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis; 13: 239-249.
18. Jorda R., Havlíček L., McNae I.W., Walkinshaw M.D., Voller J., Šturc A., Navrátilová J., Kuzma M., Mistrík M., Bártek J., Strnad M., Kryštof V., (2011) Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem; 54: 2980-2993.
19. Zatloukal M., Jorda R., Gucký T., Řezníčková E., Voller J., Pospíšil T., Malínková V., Adamcová H., Kryštof V., Strnad M., (2013) Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases. Eur J Med Chem; 61: 61-72.
20. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P., (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J; 408: 297-315.
21. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J., (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem; 30: 2785-2791.
22. Trott O., Olson A.J., (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem; 31: 455-461.
23. Weitensteiner S.B., Liebl J., Kryštof V., Havlíček L., Gucký T., Strnad M., Fürst T., Vollmar A.M., Zahler S., (2013) Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS One; 8: e54607.
24. Havlíček L., Moravcová D., Kryštof V., Strnad M,. The identification of a novel highly condensed pentacyclic heteroaromatic ring system 1,3,5,5b,6,8,10,10b-octaazacyclopenta[h,i]aceanthrylene and its application in the synthesis of 5,7-substituted pyrazolo[4,3-d]pyrimidines. J Heterocycl Chem; 52: 669-673.
25. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz P.G., (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science; 281: 533-538.
26. Chang Y.T., Gray N.S., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G., (1999) Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol; 6: 361-375.
27. Bettayeb K., Oumata N., Echalier A., Ferandin Y., Endicott J.A., Galons H., Meijer L., (2008) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene; 27: 5797-5807.
28. Bettayeb K., Sallam H., Ferandin Y., Popowycz F., Fournet G., Hassan M., Echalier A., Bernard P., Endicott J., Joseph B., Meijer L., (2008) N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther; 7: 2713-2724.
29. Oumata N., Bettayeb K., Ferandin Y., Demange L., Lopez-Giral A., Goddard M.L., Myrianthopoulos V., Mikros E., Flajolet M., Greengard P., Meijer L., Galons H., (2008) Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem; 51: 5229-5242.
30. Emanuel S., Rugg C.A., Gruninger R.H., Lin R., Fuentes-Pesquera A., Connolly P.J., Wetter S.K., Hollister B., Kruger W.W., Napier C., Jolliffe L., Middleton S.A., (2005) The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res; 65: 9038-9046.
31. Parry D., Guzi T., Shanahan F., Davis N., Prabhavalkar D., Wiswell D., Seghezzi W., et al,. (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther; 9: 2344-2353.
32. Macůrek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., Clouin C., Taylor S.S., Yaffe M.B., Medema R.H., (2008) Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature; 455: 119-123.
33. Seki A., Coppinger J.A., Jang C.Y., Yates J.R., Fang G., (2008) Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science; 320: 1655-1658.
34. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P., (2002) Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol; 22: 874-885.
35. de Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.H., (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem; 243: 518-526.
36. Shapiro G.I., (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol; 24: 1770-1783.
37. Seamon J.A., Rugg C.A., Emanuel S., Calcagno A.M., Ambudkar S.V., Middleton S.A., Butler J., Borowski V., Greenberger L.M., (2006) Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther; 5: 2459-2467.
38. David-Pfeuty T., Nouvian-Dooghe Y., Sirri V., Roussel P., Hernandez-Verdun D., (2001) Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells. Oncogene; 20: 5951-5963.
39. Demidenko Z.N., Blagosklonny M.V., (2004) Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res; 64: 3653-3660.
40. Kotala V., Uldrijan S., Horky M., Trbusek M., Strnad M., Vojtesek B., (2001) Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell Mol Life Sci; 58: 1333-1339.
41. Liebl J., Krystof V., Vereb G., Takacs L., Strnad M., Pechan P., Havlicek L., Zatloukal M., Furst R., Vollmar A.M., Zahler S., (2011) Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Angiogenesis; 14: 281-291.
42. Siemeister G., Luecking U., Wagner C., Detjen K., Mc Coy C., Bosslet K., (2006) Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother; 60: 269-272.
43. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., Koken M., et al,. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem; 280: 31208-31219.
44. Meijer L., Bettayeb K., Galons H., (2006) (R)-Roscovitine (CYC202, Seliciclib). In:, Smith P.J., Yue E.W., editors. Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents. Boca Raton, FL, USA: CRC Press: p. 187-226.
45. Krystof V., McNae I.W., Walkinshaw M.D., Fischer P.M., Muller P., Vojtesek B., Orsag M., Havlicek L., Strnad M., (2005) Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci; 62: 1763-1771.
46. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., Lane D.P., (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer; 102: 463-468.
47. Conroy A., Stockett D.E., Walker D., Arkin M.R., Hoch U., Fox J.A., Hawtin R.E., (2009) SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol; 64: 723-732.
48. Santo L., Vallet S., Hideshima T., Cirstea D., Ikeda H., Pozzi S., Patel K., et al,. (2010) AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene; 29: 2325-2336.
49. Whittaker S.R., Te Poele R.H., Chan F., Linardopoulos S., Walton M.I., Garrett M.D., Workman P., (2007) The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle; 6: 3114-3131.
50. Sroka I.M., Heiss E.H., Havlicek L., Totzke F., Aristei Y., Pechan P., Kubbutat M.H., Strnad M., Dirsch V.M., (2010) A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells. Mol Pharmacol; 77: 255-261.